Cell damage and death by autoschizis in human bladder (RT4) carcinoma cells resulting from treatment with ascorbate and menadione

Ultrastructural Pathology

Volumn 34, Issue 3, 2010, Pages 140-160

  Gilloteaux, Jacques ^a,b   Jamison, James M ^b   Neal, Deborah R ^b   Loukas, Marios ^c   Doberzstyn, Theresa ^d   Summers, Jack L ^b  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b Summa Research Foundation   (United States)

^c St George's University   (United States)

^d Children's Hospital   (United States)

Author keywords

Autoschizis; Bladder carcinoma; Cell death; RT4; Tumor cell

Indexed keywords

ANTINEOPLASTIC AGENT; ASCORBIC ACID; MENADIONE;

BLADDER TUMOR; CELL DEATH; CELL NUCLEUS; CELL ORGANELLE; CELL SURVIVAL; CONFERENCE PAPER; DNA DAMAGE; DRUG COMBINATION; DRUG EFFECT; DRUG SCREENING; HUMAN; MALE; METABOLISM; OXIDATIVE STRESS; PATHOLOGY; TRANSMISSION ELECTRON MICROSCOPY; TUMOR CELL LINE; ULTRASTRUCTURE;

ANTINEOPLASTIC AGENTS; ASCORBIC ACID; CELL DEATH; CELL LINE, TUMOR; CELL NUCLEUS; CELL SURVIVAL; DNA DAMAGE; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG THERAPY, COMBINATION; HUMANS; MALE; MICROSCOPY, ELECTRON, TRANSMISSION; ORGANELLES; OXIDATIVE STRESS; URINARY BLADDER NEOPLASMS; VITAMIN K 3;

EID: 77952272321     PISSN: 01913123     EISSN: 15210758     Source Type: Journal    
DOI: 10.3109/01913121003662304     Document Type: Conference Paper

References (124)

1. Souhami R, Tobias J. Cancer and Its Management. Malden, MA: Blackwell; 2005:315-320.
2. Crallan RA, Georgopoulos NT, Southgate J. Experimental models of human bladder carcinogenesis. Carcinogenesis. 2006;27:374-381.
3. Fisher CG, Wachter W, Fuentecilla Perez E, et al. J. Urologische Tumors in Deutschland: Ersterhebungen an 56,013 Fällen aus klinischen Krebsregistern. Urologe A. 1996;36:143-150.
4. Timberg G, Rahu M, Gornoi K, et al. Bladder cancer in Estonia, 1968-1992: incidence, mortality, prevalence and survival. Scand J Urol Nephrol. 1997;31:337-342.
5. Van den Poel HG, Mungan NA, Witjes JA. Bladder cancer in women. Int Urogynecol J Pelvic Floor Dysfunct. 1999;10:207-212.
6. Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin. 2008;58:71-96.
7. Droller MJ. Bladder cancer: state-of-the-art care. CA Cancer J Clin. 1998;48:269-284.
8. Augustine A, Hebert JR, Kabat GC, et al. Bladder cancer in relation to cigarette smoking. Cancer Res. 1988;48:4405-4408.
9. Ouellet-Hellström R, Rench JD. Bladder cancer incidence in arylamine workers. J Occup Environ Med. 1996;38:1239-1247.
10. Ward EM, Sabbioni G, DeBord DG, et al. Monitoring of aromatic exposures in worker at a chemical plant with a known bladder cancer excess. J Nat Cancer Inst. 1996;88:1046-1052.
11. Anton-Culvert H, Lee-Feldstein A, Taylor TH. The association of bladder cancer risk with ethnicity, gender, and smoking. Ann Epidemiol. 1993;3:429-433.
12. Engeland A, Andersen A, Haldorsen T, et al. Smoking habits and risk of cancer other than lung cancer: 28 years' follow-up of 26,000 Norwegian men and women. Cancer Causes Control. 1996;7:497-506. (Pubitemid 26306782)
13. Momas I, Daures JP, Festy B, et al. Bladder cancer and black tobacco cigarette smoking: some results from a French casecontrol study. Eur J Epidemiol. 1994;10:594-604.
14. Skov T, Lynge E. Cancer risks and exposures to carcinogens in hairdressers. Skin Pharm. 1998;1008(7):94-100.
15. Guo HR, Chiang HS, Hu H, et al. Arsenic in drinking water and incidence of urinary cancers. Epidemiology. 1997;8:545-550.
16. Bredfeldt TG, Jagadish B, Eblin KE, et al. Monomethylarsonous acid induces transformation of human bladder cells. Toxicol Appl Pharmacol. 2006;216:69-79.
17. Sidransky D, Frost P, Von Eschenbach A, Oyasu R, Preisinger AC, Vogelstein B. Clonal origin bladder cancer. N Engl J Med. 1992;326:737-740.
18. Lu Q-L, Laniado M, Abel PD, Stamp GWH, Lalani E-N. Expression of bcl-2 in bladder neoplasms is a cell lineage associated and p53-independent event. J Clin Pathol: Mol Pathol. 1997;50:28-33.
19. Chan TY, Epstein JI. In situ adenocarcinoma of the bladder. Am J Surg Pathol. 2001;25:892-899.
20. Shigehara K, Miyagi T, Nakshima T, Shimamura M. Cystitis glandularis forming a tumorous lesion in the urinary bladder: a rare appearance of disease. Ind J Urol. 2008;24: 558-560.
21. Burin GJ, Gibb HJ, Hill RN. Human bladder cancer: evidence for a potential irritation-induced mechanism. Food Chem Toxicol. 1995;33:785-795.
22. Abol-Enein H. Infection: is it a cause for bladder cancer? Scand J Urol Nephrol. 2008;18(Suppl 2):79-84.
23. Plail R. Detecting bladder cancer. Br Med J. 1990;301:567-568.
24. Buzzeo BD, Heisey DM, Messig EM. Bladder cancer in renal transplant recipients. Urology. 1997;50:525-528.
25. Grossman HB, Messing E, Soloway M, et al. Detection of bladder cancer using a point-of-care proteomic assay. JAMA. 2005;293:810-816.
26. Raghavan D, Shipley WU, Garnick MB. Biology and management of bladder cancer. N Engl J Med. 1990;322:1129-1138.
27. Shipley WU, Prout GR, Kaufman DS. Bladder cancer: advances in laboratory innovations and clinical management, with emphasis on innovations allowing bladder-sparing approaches for patients with invasive tumors. Cancer. 1990;65:675-683.
28. Duque JL, Loughlin KR. An overview of the treatment of superficial bladder cancer: intravesical chemotherapy. Urol Clin Am. 2000:125-136.
29. Namasivayam S, Whelan P. Intravesical mitoxantrone in recurrent superficial bladder cancer: a phase II study. Br J Urol. 1995;75:740-743.
30. Lu Z, Yeh TK, Tsai M, et al. Paclitaxel-loaded gelatin nanoparticles for intravesical bladder cancer therapy. Clin Cancer Res. 2004;10:7677-7684.
31. Apparicio AM, Elkhouiery AB, Quinn DI. The current and future application of adjuvant systemic chemotherapy in patients with bladder cancer following cystectomy. Urol Clin N Am. 2005;32:217-230.
32. Dash A, Pettus JA 4th, Herr HW, et al. A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience. Cancer. 2008;113:2471-2477.
33. Lamm DL, Thor De, Harris SC, et al. Bacillus Calmette-Guérin immunotherapy of superficial bladder cancer. J Urol. 1980;124:38-40.
34. Soloway MS. Managing superficial bladder cancer: an overview. Urology. 1992;40(Suppl 6):5-10.
35. Kuroda K, Brown EJ, Telle WB, et al. Characterization of the internalization of bacillus Calmette-Guérin by human bladder tumor cells. J Clin Invest. 1993;91:69-76.
36. Patard JJ, Guille F, Lobel B, et al. Current state of knowledge concerning the mechanism of action of BCG. Prog Urol. 1998;8:415-421.
37. Kim JC, Steinberg GD. The limits of bacillus Camette-Guérin for carcinoma in situ of the bladder. J Urol. 2001;165:745-756.
38. Brown DH, Wagner TT, Bahnson RR. Interferons and bladder cancer. Urol Clin North Am. 2000:171-178.
39. Dalbagni G, Herr HW. Current use and questions concerning intravesical bladder cancer group for superficial bladder cancer. Urol Clin North Am. 2000;27:137-146.
40. Dalbagni G. The management of superficial bladder. Cancer. 2007;4:254-260.
41. Clinton SK, Canto E, O'Donnell MA. Interleukin-12: opportunities for the treatment of bladder cancer. Urol Clin North Am. 2000;147-155.
42. Lamm DL, Riggs DR. Enhanced immunocompetence by garlic: role in bladder cancer and other malignancies. J Nutr. 2001;131:1067S-1070S.
43. Prout GR Jr, Lin CW, Benson RC, et al. Photodynamic therapy with hematoporphyrin derivative in the treatment of superficial transitional cell carcinoma of the bladder. N Engl J Med. 1987;317:1251-1255.
44. Kubota Y, Shuin T, Kawasaki C, et al. Photokilling of T24 human bladder cancer cells with titanium dioxide. Br J Cancer. 1994;70:1107-1111.
45. Frazier HA, Robertson JE, Dodge RK, et al. The value of pathologic factors in predicting cancer-specific survival among patients treated with radical cystectomy for transitional cell carcinoma of the bladder and prostate. Cancer. 1993; 71:3993-4001.
46. Stein JP, Lieskovsky G, Cote R, et al. Radical cystectyomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001;19:666-675.
47. Sternberg CN, Yagoda A, Scher HI, et al. Methotrexate, vinblastine, doxorubicin and cisplatin for advanced transitional cell carcinoma of the urothelium: efficacy and patterns of response and relapse. Cancer. 1989;64:2448-11458
48. Taper HS, de Gerlache J, Lans M, et al. Non-toxic potentiation of cancer chemotherapy by combined C and K3 vitamin pretreatment. Int J Cancer. 1987;40:575-579.
49. Taper HS, Keyeux A, Roberfroid M. Potentiation of radiotherapy by non-toxic pretreatment with combined vitamin C and K3 in mice bearing solid, transplantable tumor. Anticancer Res. 1996;16:499-503. (Pubitemid 26128515)
50. Taper HS, Roberfroid M. Non-toxic sensitization of cancer chemotherapy by combined C and K3 vitamin pretreatment in a mouse tumor resistant to oncovin. Anticancer Res. 1992;12:1651-1654.
51. Noto V, Taper HS, Jiang YH, et al. Effects of sodium ascorbate (vitamin C) and 2-methyl-1,4-naphthoquinone (vitamin K3) treatment on human tumor cell growth in vitro, I: synergism of combined vitamin C and K3 action. Cancer. 1989;63:901-906.
52. De Loecker W, Janssens J, Bonte J, et al. Effects of sodium ascorbate (vitamin C) and 2-methyl-1,4-naphthoquinone (vitamin K3) treatment on human tumor cell growth in vitro, II: synergism with combined chemotherapy action. Anticancer Res. 1993;13:103-106.
53. Taper HS, Jamison JM, Gilloteaux J, et al. Inhibition of the development of metastases by dietary vitamin C: K3 combination. Life Sci. 2004;75:955-967.
54. Buc Calderon P, Cadrobbi J, Marques C, et al. Potential therapeutic application of the association of vitamins C and K3 in cancer treatment. Curr Med Chem. 2002;9:2271-2285.
55. Verrax J, Cadrobbi J, Delvaux M, et al. The association of vitamins C and K3 kills cancer cells mainly by autoschizis, a novel form of cell death: basis for their potential use as coadjuvants in anticancer therapy. Eur J Med Chem. 2003;38:451-457.
56. Verrax J, Cadrobbi J, Marques C, et al. Ascorbate potentiates the cytotoxicity of menadione leading to an oxidative stress that kills cancer cells by a non-apoptotic caspase-3 independent form of cell death. Apoptosis. 2004;9:223-233.
57. Verrax J, Stockis J, Tison A, et al. Oxidative stress by ascorbate/ menadione association kills K562 human chronic myelogenous leukaemia cells and inhibits its tumor growth in nude mice. Biochem Pharmacol. 2006;72:671-680.
58. Gilloteaux J, Jamison JM, Vijayalasksmi M, et al. SEM and TEM aspects of synergistic antitumor activity of vitamin C-vitamin K3 combinations against human prostatic carcinoma cells. Scanning Microsc Intl. 1995;9:159-173.
59. Gilloteaux J, Jamison JM, Arnold D, et al. Cancer cell necrosis by autoschizis: synergism of antitumor activity of vitamin C:vitamin K3 on human bladder carcinoma T24 cells. Scanning. 1998;20:564-575.
60. Gilloteaux J, Jamison JM, Arnold D, et al. Autoschizis: another cell death for cancer cells induced by oxidative stress. In: Motta PM, Machiarelli G, Nottola SA, eds. Advances in microanatomy of cells and tissues, Roma. Ital J Anat Embryol. 2001;106:(Suppl 1):79-91.
61. Gilloteaux J, Jamison JM, Arnold D, et al. Ultrastructural aspects of autoschizis: a new cancer cell death induced by the synergistic action of ascorbate/menadione on human bladder carcinoma cells. Ultrastruct Pathol. 2001;25:183-192.
62. Gilloteaux J, Jamison JM, Lorimer HE, et al. Autoschizis-a new form of cell death for human ovarian carcinoma cells following ascorbate:menadione treatment: nuclear and DNA degradation. Tissue Cell. 2004;36:197-209.
63. Gilloteaux J, Jamison JM, Neal DR, et al. Cell death by autoschizis in TRAMP prostate carcinoma cells as a result of treatment by ascorbate: menadione combination. Ultrastruct Pathol. 2005;23:221-236.
64. Gilloteaux J, Jamison JM, Arnold D, et al. Morphology and DNA degeneration during autoschizic cell death in bladder carcinoma T24 cells induced by ascorbate and menadione treatment. Anat Rec A. 2006;288:58-83.
65. Ervin E, Jamison JM, Gilloteaux J, et al. Characterization of the early events in vitamin C and K3-induced death of human bladder tumor cells. Scanning. 1998;20:210-211.
66. Venugopal M, Jamison JM, Gilloteaux J et al. Synergistic antitumor activity of vitamins C and K3 against human prostate carcinoma cell lines. Cell Biol Intl. 1996;20:787-797. (Pubitemid 27075506)
67. Venugopal M, Jamison JM, Gilloteaux J, et al. Synergistic antitumor activity of vitamin C and K3 on human urologic tumor cell lines. Life Sci. 1996;59:1389-1400.
68. Jamison JM, Gilloteaux J, Taper HS, et al. Autoschizis: a novel cell death. Biochem Pharmacol. 2002;63:1773-1783.
69. Jamison JM, Gilloteaux J, Nassiri MR, et al. Cell cycle arrest and autoschizis in human bladder carcinoma cell line following vitamin C and vitamin K3 treatment. Biochem Pharmacol. 2004;67:337-351.
70. Jamison JM, Gilloteaux J, Venugopal M, et al. Flow cytometric and ultrastructural aspects of the synergistic antitumor activity of vitamin C-vitamin K3 combinations against human prostate carcinoma cells. Tissue Cell. 1996;28:687-701.
71. Taper HS, Jamison JM, Gilloteaux J, et al. In vivo reactivation of DNAses in implanted human prostate tumors after administration of vitamin C/K3 combination. J Histochem Cytochem. 2001;49:109-119.
72. Jamison JM, Gilloteaux J, Taper HS, et al. Evaluation of the in vitro and in vivo antitumor activities of vitamin C and vitamin K3 combinations against human prostate cancer. J Nutr. 2001;131:158S-160S.
73. Lasalvia-Prisco E, Cucchi S, Vazquez J, et al. Serum markers variation consistent with autoschizis induced by ascorbic acid-menadione in patients with prostate cancer. Med Oncol. 2003;20:45-52.
74. Tareen B, Summers JL, Jamison JM. A 22 week, open label, phase I/Iia study using Apatones for the treatment of prostate cancer patients who have failed standard therapy. Int J Med Sci. 2008;5:62-67.
75. Kassouf W, Highshaw R, Nelkin GM, et al. Vitamin C and K3 sensitize human urothelial tumors to gemcitabine. J Urol. 2006;176:1642-1647.
76. Karnovsky MJ. The ultrastructural basis of capillary permeability studied with peroxidase as a tracer. J Cell Biol. 1967;35:213-236.
77. Rigby C, Franks LM. A human tissue culture cell line from a transitional cell tumour of the urinary bladder: growth, chromosome pattern and ultrastructure. Br J Cancer. 1970;24:746-754.
78. Pavelic K, Kos Z, Spaventi S. Antimetabolic activity of L-ascorbic acid in human and animal tumors. Int J Biochem. 1989;21:931-935.
79. Leung PY, Miyashita K, Young M, et al. Cytotoxic effect of ascorbate and its derivatives on cultured malignant and nonmalignant cell lines. Anticancer Res. 1993;13:475-480.
80. Bram S, Froussard P, Guichard M, et al. Vitamin C preferential toxicity for malignant melanoma cells. Nature. 1980;284:629-631.
81. Park CH, Amare M, Savin MA, et al. Growth suppression for malignant leukemic cells in vitro by ascorbic acid. Cancer Res. 1979;40:1387-1392.
82. Prasad KN, Sinha PK, Ramanujam M, et al. Sodium ascorbate potentiates the growth inhibitory effect of certain agents on neuroblastoma cells in culture. Proc Natl Acad Sci USA. 1979;76:829-832.
83. Liotti FS, Menghini AR, Guerrieri P, et al. Effects of ascorbic acid and dehydroascorbic acid on the multiplication of tumor ascites cells in vitro. J Cancer Res Clin Oncol. 1984;108:230-232.
84. Koch CJ, Biaglow JE. Toxicity, radiation sensitivity modification, and metabolic effects of dehydroascorbate and ascorbate in mammalian cells. J. Cell Physiol. 1978;94:299-306.
85. Menon MM, Maramag C, Malhotra RK, et al. Effect of vitamin C on androgen independent prostate cancer cells (PC3 and Mat-Ly-Lu) in vitro: involvement of reactive oxygen specieseffect on cell number, viability and DNA synthesis. Cancer Biochem Biophys. 1998;16:17-30.
86. Morgan CD, Lefkowitz SS, Everse J. Synergism of dimethoxybenzosemiquinone free radicals and CD41 T-lymphocytes to suppress Ehrlich ascites tumor. Proc Soc Exp Biol Med 1998;217:89-96.
87. Liang W- J, Johnson D, Jarvis SM. Vitamin C transport systems of mammalian cells. Mol Membr Biol. 2001;18:87-95.
88. Agus DB, Vera JC, Golde DW. Stromal cell oxidation: amechanism by which tumors obtain vitamin C. Cancer Res. 1999;59:4555-4558.
89. Maramag C, Menon M, Blaji KC, et al. Effect of vitamin C on prostate cancer cells in vitro: effect on cell number, viability, and DNA synthesis. Prostate. 1997;32:188-195.
90. Taper HS. Reversibility of acid and alkaline deoxyribonuclease deficiency in malignant tumor cells. J Histochem Cytochem. 1980;29:1053-1060.
91. Tardy C, Codogno P, Autefage H, et al. Lysosomes and lysosomal proteins in cancer cell death (new players of an old struggle). Biochim Biophys Acta. 2006;1765:101-125.
92. Nagao N, Nakayama T, Etoh I, Saiki I, Miwa N. Tumor invasion is inhibited by phosphorylated ascorbate via enrichment of intracellular vitamin C and decreasing oxidative stress. J Cancer Res Clin Oncol. 2000;126:511-518.
93. Chlebowski RT, Dietrich M, Akman S, et al. Vitamin K3 inhibition of malignant cell growth and human tumor colony formation. Cancer Res 1985;45:5257-5262.
94. Prasad KN, Edwards-Prasad J, Sakamoto A. Vitamin K3 (menadione) inhibits the growth of mammalian tumor cells in culture. Life Sci. 1979;29:1387-1392.
95. Nutter LM, Cheng AL, Hung Hl, et al. Menadione: spectrum of anticancer therapy and effects on nucleoside metabolism in human neoplastic cell lines. Biochem Pharmacol. 1991;41:1283-1292.
96. Ngo EO, Sun TP, Chang JY, et al. Menadione-induced DNA damage in a human tumor cell line. Biochem Pharmacol. 1991;42:1961-1968.
97. Wu FY, Chang NT, Chen WJ, Juan CC. (1993a). Vitamin K3-induced cell cycle arrest and apoptotic cell death are accompanied by altered expression of c-fos and c-myc in nasopharyngeal carcinoma cells. Oncogene. 1993;8:2237-2244.
98. Wu FY, Liao WC, Chang HM. Comparison of antitumor activity of vitamins K1, K2 and K3 on human tumor cells by two (MTT and SRB) cell viability assays. Life Sci. 1993;52:1797-1804.
99. Comporti M. Three modes of free radical-induced cell injury. Chem Biol Interact. 1989;72:1-56.
100. O'Brien PJ. Molecular mechanisms of quinone cytotoxicity. Chem Biol Interact. 1991;80:1-41.
101. Jamison JM, Gilloteaux J, Taper HS, et al . The in vitro and in vivo antitumor activity of vitamin C:K3 combinations against prostate cancer. In: Lucas JN, ed. Trends in Prostate Cancer Research. Hauppauge, NY: Nova Sci, 2005;189-236.
102. Di Monte D, Bellomo G, Thor H, et al. Menadione-induced cytotoxicity is associated with protein thiol oxidation and alteration in intracellular Ca21 homeostasis. Arch Biochem Biophys. 1984;235:343-350.
103. Stubberfield CR, Cohen CR. Interconversion of NAD(H) to NADP(H). A cellular response to quinon-induced oxidative stress in isolated hepatocytes. Biochem Pharmacol. 1989;38:2631-2637.
104. Carbonera D, Azzone GF. Permeability of inner mitochondrial membrane and oxidative stress. Biochim Biophys Acta. 1988;943:245-255.
105. Bellomo G, Mirabelli F, Richelmi P, et al. The cytoskeleton as a target in quinine toxicity. Free Radic Res Commun. 1990;8:391-399.
106. Bellomo G, Mirabelli F, Vairetti M, et al. Cytoskeleton as a target in menadione-induced oxidative stress in cultured mammalian cells. J Cell Physiol. 1990;143:118-128.
107. Akman SA, Dietrich M, Chlebowski RT, et al. Modulation of cytotoxicity of menadione sodium bisulfite versus leukemia L1210 by the acid- soluble thiol pool. Cancer Res. 1985;45:5257-5262.
108. Malorni AJ, Chen C, Ingber DE. Cytoskeleton as a target in menadione- induced oxidative stress in cultured mammalian cell: alterations underlying surface blebs formation. Chem Biol Interact. 1991;80:217-223.
109. Gant TW, Rao DN, Mason R, et al. Redox cycling and sulphydryl arylation; their relative importance in the mechanism of quinone cytoxicity to isolated hepatocytes. Chem Biol Interact. 1988;65:157-173.
110. Mirabelli F, Salis A, Vairetti M, et al. Cytoskeletal alterations in human platelets exposed to oxidative stress are mediated by oxidative and Ca21-dependent mechanisms. Arch Biochem Biophys. 1989;270:478-488.
111. Bennett V. Spectrin-based membrane skeleton: a multipotential adaptor between plasma membrane and cytoplasm. Physiol Rev. 1990;70:1029-1065.
112. Subramanian V, Garcia A, Sekowski A, et al. Hydrophobic sequences target an anchor perilipin A to lipid droplets. J Lipid Res. 2004;45:1983-1991.
113. Dingova H, Fukalova JU, Maninova M, et al. Ultrastructural localization of actin and actin-binding proteins in the nucleus. Histochem Cell Biol. 2008;129:695-704.
114. Schleicher M, Jockusch BM. Actin: its cumbersome pilgrimage through cellular compartments. Histochem Cell Biol. 2008;129:695-704.
115. Cunningham CC. Actin polymerization and intracellular solvent flow in cell surface blebbing. J Cell Biol. 1995;129: 1589-1599.
116. Pething R, Gascoyne PRC, McLaughling JA, et al. Ascorbate- quinone interactions electrochemical, fre radical and cytotoxic properties. Proc Natl Acad Sci USA. 1983;80:129-132.
117. Fiorani M, De Sanctus R, Scarlatti F, et al. Dehydroascorbic acid irreversibly inhibits hexokinase activity. Mol Cell Biochem. 2000;209:145-153.
118. Fiorani M, De Sanctis R, Scarlatti F, et al. Substrates of hexokinase, glucose-6-phosphate dehydrogenase, and glyceraldehyde- 3-phosphate dehydrogenase prevent the inhibitory response induced by ascorbic acid/iron and dehydroascorbic acid in rabbit erythrocytes. Arch Biochem Biophys. 1998;356:159-166.
119. Wilson JX. The physiological role of dehydroascorbic acid. FEBS Lett. 2002;527:5-9.
120. Cárcamo JM, Pedraza A, Bórquez-Ojeda O, et al. Vitamin C suppresses TNF alpha-induced NF kappa B activation by inhibiting I kappa B alpha phosphorylation. Biochemistry. 2002;41:12995-13002.
121. Cárcamo JM, Pedraza A, Bórquez-Ojeda O, et al. Vitamin C is a kinase inhibitor: dehydroascorbic acid inhibits IkappaBalpha kinase beta. Mol Cell Biol. 2004;24:6645-6652.
122. Lockwood TD. Inactivation of intracellular proteolysis and cathepsin B enzyme activity by dehydroascorbic acid and reactivation by dithiotreitol in perfused rat heart. Biochem Pharmacol. 1997;54:669-675.
123. Bianchi J, Rose RC. Dehydroascorbic acid and cell membranes: possible disruptive effects. Toxicology. 1986;40:75-82.
124. Dunn JA, Ahmed MU, Murtiashaw MH, et al. Reaction of ascorbate with lysine and protein under autoxidizing conditions: formation of N-epsilon-(carboxymethyl) lysine by reaction between lysine and products of autoxidation of ascorbate. Biochemistry. 1990;29:10964-10970.